Journal: Analytical and Bioanalytical Chemistry

Article Title: Conductive vial electromembrane extraction of opioids from oral fluid

doi: 10.1007/s00216-023-04807-3

Figure Lengend Snippet: Validation data of opioids: coefficient of correlation ( R ), precision (CV%), and accuracy (bias%) at the lower limit of quantification (LLOQ) and three QC levels, recoveries (RE), matrix effects (ME), and internal standard corrected matrix effects. The quantification range was from LLOQ to 50 × LLOQ for all analytes

Article Snippet: Codeine, cyclopropylfentanyl, ethylmorphine-d 5 , fentanyl-d 5 methadone-d 3 , morphine, N-pyrrolidino etonitazene (etonitazepyne), methadone, oxycodone, oxycodone-d 6 and tramadol-d 6 were from Chiron (Trondheim, Norway).

Techniques: Concentration Assay

Journal: Analytical Chemistry

Article Title: Electrochemical Detection of Oxycodone and Its Main Metabolites with Nafion-Coated Single-Walled Carbon Nanotube Electrodes

doi: 10.1021/acs.analchem.0c00450

Figure Lengend Snippet: Characterization of the Nafion/SWCNT electrode. (A) Nafion concentration. 5 μM oxycodone with SWCNT with 2.5% Nafion and 5% Nafion. (B) Accumulation time. 5 μM oxycodone measured with SWCNT 2.5% Nafion with accumulation times 0, 5, 10, and 15 min.

Article Snippet: Oxycodone hydrochloride powder and noroxycodone hydrochloride powder were purchased from Toronto Research Chemicals, Canada.

Techniques: Concentration Assay

Journal: Analytical Chemistry

Article Title: Electrochemical Detection of Oxycodone and Its Main Metabolites with Nafion-Coated Single-Walled Carbon Nanotube Electrodes

doi: 10.1021/acs.analchem.0c00450

Figure Lengend Snippet: Suggested electrochemical behavior of oxycodone and metabolites. 10 μM oxycodone (blue), 10 μM noroxycodone (green), and 10 μM oxymorphone (red) measured with (A) a plain SWCNT electrode with no accumulation time and (B) a Nafion/SWCNT electrode with 5 min accumulation time. Color bars highlight the oxidation peaks, tentatively assigned to two different functional groups, also indicated with corresponding colored circles in the chemical structures of oxycodone and the metabolites.

Article Snippet: Oxycodone hydrochloride powder and noroxycodone hydrochloride powder were purchased from Toronto Research Chemicals, Canada.

Techniques: Functional Assay

Journal: Analytical Chemistry

Article Title: Electrochemical Detection of Oxycodone and Its Main Metabolites with Nafion-Coated Single-Walled Carbon Nanotube Electrodes

doi: 10.1021/acs.analchem.0c00450

Figure Lengend Snippet: Concentration series for oxycodone. (A) Oxycodone with concentrations 0.5, 1, 2.5, 5, 7.5, and 10 μM with an accumulation time of 5 min. (B) Average oxidation peak currents as a function of oxycodone concentration. Error bars show the standard deviations of the peak currents ( n = 4).

Article Snippet: Oxycodone hydrochloride powder and noroxycodone hydrochloride powder were purchased from Toronto Research Chemicals, Canada.

Techniques: Concentration Assay

Journal: Analytical Chemistry

Article Title: Electrochemical Detection of Oxycodone and Its Main Metabolites with Nafion-Coated Single-Walled Carbon Nanotube Electrodes

doi: 10.1021/acs.analchem.0c00450

Figure Lengend Snippet: Stability of the sensor. (A) Electrode signal stability; 5 μM oxycodone measured with one SWCNT 2.5% Nafion 6 times in a row. (B) Long-term stability. Three electrodes measured in 5 μM oxycodone after storing for 1, 8, 15, and 22 days after coating. Data shows the differences in the average values in the oxycodone peak current relative to day 1 in percentages as a function of days after coating.

Article Snippet: Oxycodone hydrochloride powder and noroxycodone hydrochloride powder were purchased from Toronto Research Chemicals, Canada.

Techniques:

Journal: Analytical Chemistry

Article Title: Electrochemical Detection of Oxycodone and Its Main Metabolites with Nafion-Coated Single-Walled Carbon Nanotube Electrodes

doi: 10.1021/acs.analchem.0c00450

Figure Lengend Snippet: Oxycodone and metabolites without and with 2.5% Nafion; 5 μM oxycodone (blue), 3.75 μM noroxycodone (green), and 250 nM oxymorphone (red) without Nafion (A) and with Nafion (B); 5 μM oxycodone (blue) and 5 μM oxycodone in the presence of the two metabolites, 3.75 μM noroxycodone and 250 nM oxymorphone (black dash), without Nafion (C) and with Nafion (D).

Article Snippet: Oxycodone hydrochloride powder and noroxycodone hydrochloride powder were purchased from Toronto Research Chemicals, Canada.

Techniques:

Journal: RSC Advances

Article Title: A high-throughput bioanalytical assay to support pharmacokinetic interaction study of oxycodone and diazepam in Sprague Dawley rats

doi: 10.1039/c9ra05785d

Figure Lengend Snippet: Product ion mass spectra of [M + H] + of oxycodone m / z 316 → 298 (A), oxycodone-d 6 m / z 322 → 304 (B) diazepam m / z 285 → 154 (C) and diazepam-d 5 m / z 290 → 198 (D).

Article Snippet: Internal standards (ISs) oxycodone-d 6 and diazepam-d 5 were obtained from Cerilliant (Round Rock, TX, USA).

Techniques:

Journal: RSC Advances

Article Title: A high-throughput bioanalytical assay to support pharmacokinetic interaction study of oxycodone and diazepam in Sprague Dawley rats

doi: 10.1039/c9ra05785d

Figure Lengend Snippet: Typical MRM chromatograms of oxycodone (left panel) and oxycodone-d 6 (right panel) in blank plasma (A), blank plasma with IS1 (B), an LLOQ sample (C), a 3.0 h in vivo sample (D).

Article Snippet: Internal standards (ISs) oxycodone-d 6 and diazepam-d 5 were obtained from Cerilliant (Round Rock, TX, USA).

Techniques: In Vivo

Journal: Journal of Pain Research

Article Title: Bunionectomy as an Acute Postoperative Pain Model: Overview of Common Experimental Methods, and Insights from Past Clinical Trials

doi: 10.2147/JPR.S466723

Figure Lengend Snippet: Postoperative Acute Pain Drug Approvals Since 2008 (US and/or EU)

Article Snippet: 10/14 , 06/15 , (dexmedetomidine) [DEX-IN] , Baudax , NCT02284243 , Alpha-2 agonist , Intranasal , 2 , 168 , 2 , None , Oxycodone , 3 , POD1 , 6.5 , SPID48 , 0.018 , 0.301.

Techniques:

Journal: Journal of Pain Research

Article Title: Bunionectomy as an Acute Postoperative Pain Model: Overview of Common Experimental Methods, and Insights from Past Clinical Trials

doi: 10.2147/JPR.S466723

Figure Lengend Snippet: Bunionectomy Studies

Article Snippet: 10/14 , 06/15 , (dexmedetomidine) [DEX-IN] , Baudax , NCT02284243 , Alpha-2 agonist , Intranasal , 2 , 168 , 2 , None , Oxycodone , 3 , POD1 , 6.5 , SPID48 , 0.018 , 0.301.

Techniques: Blocking Assay

Journal: Pain Medicine: The Official Journal of the American Academy of Pain Medicine

Article Title: A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone

doi: 10.1093/pm/pnv020

Figure Lengend Snippet: Summary statistics: oxycodone PK parameters

Article Snippet: Oxycodone DETERx® (Xtampza™ ER [oxycodone extended-release]; herein “DETERx”) (Collegium Pharmaceutical, Inc., Canton, MA, USA; herein “Collegium”) is an experimental, oral, extended-release oxycodone with a novel abuse-deterrent formulation.

Techniques:

Journal: Pain Medicine: The Official Journal of the American Academy of Pain Medicine

Article Title: A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone

doi: 10.1093/pm/pnv020

Figure Lengend Snippet: Mean plasma oxycodone concentration (ng/mL) over time (hours) for crushed DETERx IN, intact DETERx PO, and crushed OXY-IR IN recorded at multiple time points following administration of study drug. Error bars = ±Standard Deviation. hrs =hours; IN = intranasal; mL = milliliter; ng = nanogram; OXY = oxycodone; OXY-IR = immediate-release oxycodone; PO = per os.

Article Snippet: Oxycodone DETERx® (Xtampza™ ER [oxycodone extended-release]; herein “DETERx”) (Collegium Pharmaceutical, Inc., Canton, MA, USA; herein “Collegium”) is an experimental, oral, extended-release oxycodone with a novel abuse-deterrent formulation.

Techniques: Concentration Assay, Standard Deviation

Journal: Pain Medicine: The Official Journal of the American Academy of Pain Medicine

Article Title: A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone

doi: 10.1093/pm/pnv020

Figure Lengend Snippet: Mean VAS scores for (a) Drug Liking (bipolar VAS), (b) Drug High (unipolar VAS), and (c) Good Effects (unipolar VAS) during the Double-blind Treatment Phase (N = 36). Each graph shows arithmetic mean VAS results observed during 24 hours for the four treatment conditions: A (●) = crushed DETERx IN; B (□) = intact DETERx PO; C (▵)= crushed OXY-IR IN; D (○) = Placebo. Higher scores denote greater response on the respective PD drug-attractiveness variable; error bars are omitted for clarity purposes. DEQ = drug effects questionnaire; IN = intranasal; mm = millimeter; N = number of observations; OXY = oxycodone; OXY-IR = immediate-release oxycodone; PD = pharmacodynamic; PO = per os; VAS = visual analog scale.

Article Snippet: Oxycodone DETERx® (Xtampza™ ER [oxycodone extended-release]; herein “DETERx”) (Collegium Pharmaceutical, Inc., Canton, MA, USA; herein “Collegium”) is an experimental, oral, extended-release oxycodone with a novel abuse-deterrent formulation.

Techniques:

Journal: Pain Medicine: The Official Journal of the American Academy of Pain Medicine

Article Title: A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone

doi: 10.1093/pm/pnv020

Figure Lengend Snippet: Cumulative plot of percent reduction in Drug Liking E max for DETERx IN relative to OXY-IR IN in the Double-blind Treatment Phase (N = 36). The vertical Y-axis represents the percent of subjects attaining a percent reduction of Drug Liking for DETERx IN vs OXY-IR IN equal to or greater than the value on the horizontal X-axis. ‘> =’ symbol = greater than or equal to; E max = peak effect; IN = intranasal; IR = immediate-release; N = number of observations; OXY = oxycodone.

Article Snippet: Oxycodone DETERx® (Xtampza™ ER [oxycodone extended-release]; herein “DETERx”) (Collegium Pharmaceutical, Inc., Canton, MA, USA; herein “Collegium”) is an experimental, oral, extended-release oxycodone with a novel abuse-deterrent formulation.

Techniques:

Journal: Pain Medicine: The Official Journal of the American Academy of Pain Medicine

Article Title: A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone

doi: 10.1093/pm/pnv020

Figure Lengend Snippet: Arithmetic mean results of pupillometry measures during the Double-blind Treatment Phase, encompassing 8 hours of observation in study subjects (N = 36). Treatments: A (●) = crushed DETERx IN; B (□) = intact DETERx PO; C (▵)= crushed OXY-IR IN; D (○) = Placebo. Larger decreases indicate more pupil constriction denoting a greater drug effect; error bars are omitted for clarity purposes. IN = intranasal; IR = immediate-release; mm = millimeter; N = number of observations; OXY = oxycodone; PO = per os.

Article Snippet: Oxycodone DETERx® (Xtampza™ ER [oxycodone extended-release]; herein “DETERx”) (Collegium Pharmaceutical, Inc., Canton, MA, USA; herein “Collegium”) is an experimental, oral, extended-release oxycodone with a novel abuse-deterrent formulation.

Techniques: